PSDV Profile
pSivida Corp. (PSDV) is a pharmaceutical company that develops and commercializes innovative ophthalmic products for the treatment of chronic eye diseases. The company's lead product is a sustained-release implant that delivers drugs directly to the back of the eye to treat diabetic retinopathy and age-related macular degeneration.
PSDV's sustained-release implant technology, known as Durasert, allows for long-term drug delivery to the back of the eye, reducing the need for frequent injections and improving patient compliance. The company has also developed a proprietary bioerodible implant technology, which enables the sustained release of drugs over an extended period of time.
In addition to its ophthalmic products, PSDV is exploring the use of its implant technology in other therapeutic areas, such as oncology and infectious diseases. The company has partnerships with several leading pharmaceutical companies to develop and commercialize its products.
As of the market close on February 23, 2023, PSDV had a market capitalization of approximately $70 million.
|
